Nurix Therapeutics, Inc. (NRIX) - 10-K Summary
Business Context and Reporting Period
Company: Nurix Therapeutics, Inc.
Filing Type: Form 10-K (Annual Report)
Fiscal Year Ended: November 30, 2025
Business Overview: Nurix is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines for cancer and inflammatory diseases. The company utilizes a proprietary DNA-encoded library and artificial intelligence (DEL-AI) platform to discover degraders and degrader antibody conjugates (DACs).
Key Assets: The wholly owned pipeline includes three clinical-stage candidates: bexobrutideg (BTK degrader), zelebrudomide (BTK/IKZF1/3 degrader), and NX-1607 (CBL-B inhibitor). The company also maintains strategic collaborations with Gilead, Sanofi, and Pfizer.
Key Financial Metrics
| Metric (in millions) | Fiscal 2025 | Fiscal 2024 | Change |
|---|---|---|---|
| Total Revenue | $84.0 | $54.5 | +$29.5 |
| Collaboration Revenue | $54.0 | $54.5 | -$0.5 |
| License Revenue | $30.0 | $0.0 | +$30.0 |
| Operating Expenses | $369.6 | $267.6 | +$102.0 |
| R&D Expenses | $316.9 | $221.6 | +$95.3 |
| G&A Expenses | $52.7 | $45.9 | +$6.8 |
| Net Loss | $(264.5) | $(193.6) | $(70.9) |
| Cash & Equivalents | $592.9 | $609.6 | $(16.7) |
| Accumulated Deficit | $(1,003.2) | $(738.8) | N/A |
Note: Cash and equivalents includes marketable securities. The filing does not provide a specific "Debt" line item; the company has no long-term debt obligations listed on the balance sheet.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 54% year-over-year, driven primarily by $30.0 million in license revenue from Sanofi (related to two license extensions) and increased collaboration revenue from Pfizer ($25.7M vs $18.8M). Collaboration revenue from Gilead and Sanofi decreased slightly due to the conclusion of initial research terms.
- Expense Increase: Operating expenses rose 38%, with R&D expenses increasing 43%. This was driven by higher clinical costs for bexobrutideg (NX-5948) as the company accelerated enrollment in Phase 2 trials, increased contract manufacturing costs, and higher personnel costs.
- Net Loss Expansion: Net loss widened to $264.5 million from $193.6 million, reflecting the significant increase in R&D investment outpacing revenue growth.
- Liquidity: Cash, cash equivalents, and marketable securities decreased slightly to $592.9 million. The company raised $234.4 million in net proceeds from a registered direct offering in October 2025.
Guidance, Outlook, and Risks
Outlook and Milestones:
- Bexobrutideg (NX-5948): Enrollment is ongoing in the pivotal Phase 2 study (DAYBreak CLL-201) for relapsed/refractory CLL. The company intends to commence additional trials in 2026 to support registration. Fast Track designation was granted by the FDA for CLL and Waldenström's macroglobulinemia (WM).
- Zelebrudomide (NX-2127): Dose escalation is ongoing with a new drug form following the resolution of a partial clinical hold in August 2024. Focus is on aggressive B-cell lymphomas (DLBCL, MCL).
- NX-1607: Phase 1a/1b dose escalation is ongoing in solid tumors. The company expects to define doses for Phase 1b cohort expansion in 2026.
- Collaborations: The company expects to earn multiple preclinical and clinical milestones from Gilead, Sanofi, and Pfizer in 2026.
Liquidity Outlook: Management believes existing cash resources ($592.9 million) are sufficient to fund operations for at least the next 12 months. Substantial additional funding will be required to complete development and commercialization.
Key Risks:
- Clinical Development: High risk of failure in clinical trials; potential for delays or clinical holds (as previously experienced with zelebrudomide).
- Capital Needs: The company has never generated product revenue and expects to incur losses for several years. Failure to raise capital could force program delays.
- Regulatory: Dependence on FDA/EMA approvals; potential for unfavorable pricing regulations or reimbursement policies.
- Manufacturing: Reliance on third-party contract manufacturing organizations (CMOs), including some in China, exposing the company to supply chain and tariff risks.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $592.9 million cash balance against the projected burn rate, given the significant increase in R&D spend.
- Phase 2 Enrollment: Monitor the pace of patient enrollment in the pivotal bexobrutideg Phase 2 trial (DAYBreak CLL-201) and any updates on the 600mg dose efficacy.
- Sanofi License Revenue: Confirm the recognition of the $30 million license revenue and the status of the two licensed targets (First and Second Sanofi License Extensions).
- Manufacturing Supply Chain: Assess the impact of recent U.S. tariffs on goods from China, where some third-party manufacturers are located, on drug supply and costs.
- Pre-funded Warrants: Review the dilution risk associated with the 7.58 million outstanding pre-funded warrants exercisable at $0.001.